The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
HOME > BUSINESS
BUSINESS
- CMIC MPSS to Offer Comprehensive Region-Wide CSO Service for Long-Listed Drugs
November 30, 2012
- China’s Drug Costs to Expand to 11 Trillion Yen in 2030 by 5% Annual Growth: UtoBrain
November 29, 2012
- Long-Listed Products to Be Switched to Combination Drugs, Original Drugs Rather than Generics: President Sawai
November 29, 2012
- Sawai to Seek Alternative Suppliers for All of Its Products
November 29, 2012
- Santen Files Anti-Allergic Ophthalmic Solution DE-114
November 29, 2012
- Chugai, Nippon Shinyaku Conclude Codevelopment, Comarketing Agreement for Anti-CD20 Antibody
November 29, 2012
- Takeda to Establish Medical Affairs Department within Development Division
November 28, 2012
- Approximately 30% of Doctors Conduct ALK Gene Test in All Patients: Pfizer Survey
November 28, 2012
- Pfizer Launches Glycylcycline Antibiotic Tygacil
November 27, 2012
- 8 Companies’ Entries to COPD Market Turn It into Red Ocean
November 27, 2012
- Bayer Eyes Sales of €3 Billion in Japan by 2017: Chairman Dekkers
November 27, 2012
- Health Professionals Voice Concerns over JPMA Transparency Guidelines
November 26, 2012
- Teva Pharma to Temporarily Discontinue Marketing of Risperidone Generics Due to Halt in Bulk Drug Production
November 26, 2012
- Fuji Pharma, Mochida Receive Approvals for Biosimilar Gran
November 26, 2012
- Decline in Sales of Long-listed Drugs Continues with a Double-punch from Generics, NHI Price Reductions
November 26, 2012
- Joint Venture with Actavis to Continue Operations: ASKA Pres. Yamaguchi
November 22, 2012
- Astellas Submits Supplemental NDA in US for Tarceva
November 22, 2012
- MSD to Promote Joint Detailing by Sales Units Specialized in Different Therapeutic Fields: Vice Pres. Kotani
November 22, 2012
- Bayer to Initiate PIII Study of Xarelto for Prevention of MACE in Patients with CAD/PAD, Considers Study in Japan as Well
November 22, 2012
- Japanese Ethical Drug Market Shows Negative Growth in July-September for the First Time in 7 Quarters: IMS Japan
November 21, 2012
ページ
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…